Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug
Dive Brief:
Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to Cullinan Oncol...
Continue Reading →
